GLP-1 and Engineered Microbe Therapy for Obesity-Related Muscle Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for obesity do not address muscle loss and atrophy, and existing methods for inhibiting myostatin function are economically inefficient and pose health risks, while GLP-1 receptor agonists do not treat muscle loss related to obesity.
Innovation Solution
A combination therapy using a microorganism transformed with a cell surface display vector expressing myostatin and activin A as a bispecific antigen, combined with an approved GLP-1 receptor agonist, to treat muscle loss due to obesity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If myostatin inhibition methods are used to treat muscle loss, then muscle mass increases, but economic efficiency decreases and health risks increase
Solution Approach 1:
The patent uses a bispecific antibody as an intermediary that simultaneously binds to both myostatin and activin A, blocking their harmful effects without directly introducing foreign proteins or genes. This mediator approach achieves muscle growth while avoiding the safety issues of direct myostatin inhibition and the economic inefficiency of complex biologic production
Solution Approach 2:
The invention employs a bispecific antibody composition that combines specificity for both myostatin and activin A into a single therapeutic agent. This composite biological material provides dual functionality, addressing multiple aspects of muscle regulation simultaneously while improving economic efficiency through a single-product formulation
2Weight of moving object
If GLP-1 receptor agonist alone is used for obesity treatment, then weight loss is achieved, but muscle loss is not addressed
Solution Approach 1:
The patent combines GLP-1 receptor agonist therapy with bisspecific antibody treatment in a single composition or concurrent administration regimen. This merging of therapies allows simultaneous achievement of weight loss through GLP-1 mechanism and muscle mass preservation through myostatin/activin A blockade, solving the problem of muscle loss during obesity treatment
Solution Approach 2:
The bisspecific antibody provides multi-functional benefits by simultaneously targeting both myostatin and activin A pathways, while being compatible with GLP-1 agonist therapy. This universal approach addresses multiple physiological systems (weight regulation and muscle maintenance) with a single additional agent
Data Source
AI summary
The present invention relates to a combination therapy of an approved GLP-1 receptor agonist treatment and a microorganism transformed with a cell surface display vector operably linked with a gene encoding myostatin and activin A proteins for the treatment of muscle loss related to obesity. The microorganism may be formulated to include pharmaceutically viable excipients, such as antiadherents, binders, carriers, coatings, colorants, disintegrants, diluents, flavorings, glidants, lubricants, preservatives, sorbents, or vehicles.